| (84) |
Designated Contracting States: |
|
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
| (30) |
Priority: |
19.06.2000 US 212466 P
|
| (43) |
Date of publication of application: |
|
22.06.2011 Bulletin 2011/25 |
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
01946572.3 / 1297017 |
| (73) |
Proprietors: |
|
- Beth Israel Deaconess Medical Center
Boston, MA 02215 (US)
- Dana-Farber Cancer Institute, Inc.
Boston, MA 02215-5450 (US)
- The General Hospital Corporation
Boston, MA 02114 (US)
|
|
| (72) |
Inventors: |
|
- Exley, Mark A.
Chestnut Hill, MA 02467-1426 (US)
- Wilson, Samuel B.
Micanopy, FL 32667 (US)
- Balk, Steven P.
Needham, MA 02492 (US)
|
| (74) |
Representative: Bösl, Raphael Konrad |
|
Isenbruck Bösl Hörschler LLP
Patentanwälte
Prinzregentenstraße 68
81675 München
81675 München (DE) |
| (56) |
References cited: :
EP-A- 0 677 533
WO-A-99/34209
|
EP-A- 1 025 854
|
|
| |
|
|
- EXLEY MARK ET AL: "CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human
T cells expressing invariant Valpha24JalphaQ T cell receptor alpha chains.", JOURNAL
OF EXPERIMENTAL MEDICINE, vol. 188, no. 5, 7 September 1998 (1998-09-07), pages 867-876,
XP001074739, ISSN: 0022-1007
- NICOL A ET AL: "Human invariant Valpha24+ natural killer T cells activated by alpha-galactosylceramide
(KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells
and natural killer cells.", IMMUNOLOGY., vol. 99, no. 2, February 2000 (2000-02),
pages 229-234, XP001073724, ISSN: 0019-2805
- WILSON S BRIAN ET AL: "Development of monoclonal antibodies to Valpha24JalphaQ T cells
detects alterations in cell frequency in new-onset type 1 diabetes patients.", DIABETES,
vol. 50, no. Supplement 2, June 2001 (2001-06), page A267, XP008004082, 61st Scientific
Sessions of the American Diabetes Association;Philadelphia, Pennsylvania, USA; June
22-26, 2001 ISSN: 0012-1797
- VLIET VAN DER H J J ET AL: "EFFECTS OF ALPHA-GALACTOSYLCERAMIDE (KRN7000), INTERLEUKIN-12
AND INTERLEUKIN-7 ON PHENOTYPE AND CYTOKINE PROFILE OF HUMAN VALPHA24+ VBETA11+ T
CELLS", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 98, no. 4, 1 December 1999
(1999-12-01), pages 557-563, XP008019160, ISSN: 0019-2805, DOI: 10.1046/J.1365-2567.1999.00920.X
- VAN DER VLIET HANS J J ET AL: "Circulating myeloid dendritic cells of advanced cancer
patients result in reduced activation and a biased cytokine profile in invariant NKT
cells", JOURNAL OF IMMUNOLOGY, vol. 180, no. 11, June 2008 (2008-06), pages 7287-7293,
XP002664613, ISSN: 0022-1767
- MACDONALD H ROBSON: "CD1d-glycolipid tetramers: A new tool to monitor natural killer
T cells in health and disease", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 192, no. 5,
4 September 2000 (2000-09-04), pages F15-F19, ISSN: 0022-1007
- EXLEY MARK A ET AL: "Selective activation, expansion, and monitoring of human iNKT
cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop", EUROPEAN
JOURNAL OF IMMUNOLOGY, vol. 38, no. 6, June 2008 (2008-06), pages 1756-1766, ISSN:
0014-2980
- FREDERICKSON SHANA ET AL: "A rationally designed agonist antibody fragment that functionally
mimics thrombopoietin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL
ACADEMY OF SCIENCES, US, vol. 103, no. 39, 1 September 2006 (2006-09-01), pages 14307-14312,
XP009102615, ISSN: 0027-8424, DOI: 10.1073/PNAS.0602658103
|
|
